Практические рекомендации по антибактериальной терапии инфекций у пациентов с нейтропенией

Клиническая Микробиология и Антимикробная Химиотерапия. 2003; 5(1):47-73

​ Клясова Г.А.
нейтропеническая лихорадка нейтропения антибиотики антимикробная химиотерапия
Раздел
Методические рекомендации
Тип
Журнальная статья
Публикация
Клиническая Микробиология и Антимикробная Химиотерапия. 2003; 5(1):47-73

Аннотация

Нейтропеническая лихорадка становится всё более актуальной проблемой стационаров лечебно-профилактических учреждений России. Меняющийся спектр возбудителей инфекций, рост их антибиотикорезистентности, увеличение числа пациентов, относящихся к контингенту с факторами риска развития нейтропенической лихорадки, требуют не только пристального внимания клиницистов к данной проблеме, но и разработки четких рекомендаций по ведению таких больных. В настоящее время наиболее полноценными рекомендациями по ведению пациентов с фебрильной нейтропенией, на наш взгляд, являются рекомендации Американского общества инфекционных болезней (IDSA). В связи с этим данная статья представляет собой попытку адаптировать указанные рекомендации к российским условиям. В статье рассмотрены вопросы диагностики и стратификации факторов риска у пациентов данной группы. Описан выбор препаратов для эмпирической и этиотропной терапии. Рассмотрены возможности антибиотикотерапии нейтропенической лихорадки. Приведены рекомендации по оценке эффективности терапии, методики ее модификации и определения продолжительности лечения. Даны рекомендации по применению противовирусных препаратов, колониестимулирующих факторов и трансфузий гранулоцитарной массы. Освещены вопросы антибиотикопрофилатики нейтропенической лихорадки.

  • 1. Shughes W.T., Armstrong D., BodeyG.P., et al. 1997 guidelines for theuse of antimicrobial agents in neu-tropenic patients with unexplainedfever. Infectious Diseases Society ofAmerica. Clin Infect Dis 1997;25:551-73.
  • 2. Bodey G.P., Buckley M., Sathe Y.S.,Freireich E.J. Quantitative rela-tionships between circulatingleukocytes and infection in patientswith acute leukemia. Ann InternMed 1966; 64:328-40.
  • 3. Schimpff S.C. Empiric antibiotic the-rapy for granulocytopenic cancerpatients. Am J Med 1986; 80:13-20.
  • 4. Lucas K.G., Brown A.E., Armstrong D., et al. The identificationof febrile, neutropenic childrenwith neoplastic disease at low riskfor bacteremia and complications ofsepsis. Cancer 1996; 77:791-8.
  • 5. Dale D.C., Guerry D. 4th, We-werka J.R., Chusid M.J. Chronicneutropenia. Medicine (Baltimore)1979; 58:128-44.
  • 6. Sickles E.A., Greene W.H., Wier-nik P.H. Clinical presentation ofinfection in granulocytopenic pati-ents. Arch Intern Med 1975;135:715-9.
  • 7. Mermel L.A., Farr B.M., Sheretz R.J.,et al. Guidelines for the manage-ment of intravascular catheter-related infection. Clin Infect Dis2001; 32:1249-72.
  • 8. Weinstein M.P. Current blood cul-ture methods and systems: clinicalconcepts, technology, and interpre-tation of results. Clin Infect Dis1996; 23:40-60.
  • 9. Adamkiewicz T.V., Lorenzana A.,Doyle J., et al. Peripheral vs. centralblood cultures in patients admittedto a pediatric oncology ward. Pedi-atr Infect Dis J 1999; 18:556-8.
  • 10. Whimbey E., Wong B., Kiehn T.E.,Armstrong D. Clinical correlationsof serial quantitative blood culturesdetermined by lysis-centrifugatio-nin patients with persistent sep-ticemia. J Clin Microbiol 1984;19:766-71.
  • 11. Rolston R.V.I., Balakrishnan M.,Elting L.S., et al. Is quantitativevariation in cancer patients withbacteremic infections linked toseverity of infection? [Abstract729]. In: Program and abstracts ofthe 40th Interscience Conferencefor Antimicrobial Agents andChemotherapy (Toronto). Wa-shington, DC: American Society forMicrobiology, 2000.
  • 12. McDonald L.C., Weinstein M.P.,Mirrett S., et al. Controlled com-parison of BacT/ALERT FANaerobic medium and VATEC fun-gal blood culture medium for detec-tion of fungemia. J Clin Microbiol2001; 39:622-4.
  • 13. Weinstein M.P., Mirrett S., Wil-son M.L., et al. Controlled evalua-tion of 5 versus 10 milliliters ofblood cultured in aerobicBacT/Alert blood culture bottles.J Clin Microbiol 1994; 32:2103-6.
  • 14. Flynn P.M., Van Hooser B., Gigli-otti F. Atypical mycobacterialinfections of Hickman catheter exitsites. Pediatr Infect Dis J 1988;7:510-3.
  • 15. Bodey G.P., Fainstein V. Systemiccandidiasis. In: Bodley G.P., Fain-stein V., eds. Candidiasis. NewYork: Raven Press, 1985. p.135-68.
  • 16. Guerrant R.L., Van Gilder T., Stei-ner T.S., et al. Practice guidelinesfor the management of infectiousdiarrhea. Clin Infect Dis 2001;32:331-50.
  • 17. Heussel C.P., Kauczor H.U., Heus-sel G.E., et al. Pneumonia in febrileneutropenic patients and in bonemarrow and blood stem cell trans-plant recipients: use of high resolu-tion computed tomography. J ClinOncol 1999; 17:796-805.
  • 18. Allen U., Smith C.R., Prober C.G.The value of skin biopsies in febrile,neutropenic, immunocompromisedchildren. Am J Dis Child 1986;140:459-61.
  • 19. Lehrnbecher T., Venzon D., deHaas M., et al. Assessment of mea-suring circulating levels of inter-leukin-6, interleukin-8, C-reactiveprotein, soluble Fcγreceptor typeIII, and mannose-binding protein infebrile children with cancer andneutropenia. Clin Infect Dis 1999;29:414-9.
  • 20. Engel A., Steinbach G., Kern P., etal. Diagnostic value of procalci-tonin serum levels in Neutropenicpatients with fever: comparisonwith interleukin-8. Scand J InfectDis 1999; 31:185-9.
  • 21. Kern W.V., Heiss M., Steinbach G.,et al. Prediction of gram-negativebacteremia in patients with cancerand febrile neutropenia by means ofinterleukin-8 levels in serum:targeting empirical monotherapyversus combination therapy. ClinInfect Dis 2001; 32:832-5.
  • 22. Engel A., Mack E., Kern P., et al. Ananalysis of interleukin-8, inter-leukin-6, and C-reactive proteinserum concentrations to predictfever, gram-negative bacteremia,and complicated infection in neu-tropenic cancer patients. Infection1998; 26:213-21.
  • 23. Bochud P.Y., Calandra T., Franci-oli P. Bacteremia due to viridansstreptococci in neutropenic pati-ents: a review. Am J Med 1994;97:256-64.
  • 24. Pizzo P.A., Ladisch S., Robicha-ud K. Treatment of gram-positivesepticemia in cancer patients.Cancer 1980; 45:206-7.
  • 25. Rolston K.V.I., Tarrand J.J.Pseudomonas aeruginosa– still a frequentpathogen in patients with cancer:11-year experience at a comprehen-sive cancer center. Clin Infect Dis1999; 29:463-4.
  • 26. Escande M.C., Hebrect R. Pro-spective study of bacteremia in can-cer patients. Support Care Cancer1998; 6:273-80.
  • 27. Collioud D., van der Auwera P.,Viot M., et al. Prospective multi-centric study of the etiology of1051 bacteremic episodes in 782cancer patients. Support CareCancer 1993; 1:34-6.
  • 28. Al-Bahar S., Pandita R., Dhab-har B.N., et al. Febrile neutropeniain cancer patients in Kuwait: micro-bial spectrum and outcome. SupportCare Cancer 1994; 2:400-2.
  • 29. Spanik S., Stopkova K., Grau-sova S., et al. Postoperative bac-teremia in cancer patients withsolid tumors undergoing surgery:risk factors, etiology and outcomein 276 patients. Support CareCancer 1997; 5:336-8.
  • 30. European Organization for Rese-arch and Treatment of Cancer(EORTC) International Anti-microbial Therapy CooperativeGroup, National Cancer Instituteof Canada – Clinical Trials Group.Vancomycin added to empiricalcombination antibiotic therapy forfever in granulocytopenic cancerpatients. J Infect Dis 1991;163:951-8.
  • 31. Douard M.C., Arlet G., Longuet P.,et al. Diagnosis of venous accessport–related infections. Clin InfectDis 1999; 29:1197-202.
  • 32. Benezra D., Kiehn T.E., Gold J.W.,et al. Prospective study of infec-tions in indwelling central venouscatheters using quantitative bloodcultures. Am J Med 1988; 85:495-8.
  • 33. Raad I.I., Vartivarian S., Khan A., etal. Catheter-related infections cau-sed by theMycobacterium fortuitum complex: 15 cases and review. RevInfect Dis 1991; 13:1120-5.
  • 34. Viscoli C., Bruzzi P., Glauser M. Anapproach to the design and imple-mentation of clinical trails of empi-rical antibiotic therapy in febrileand neutropenic cancer patients.Eur J Cancer 1995; 31A:2013-22.
  • 35. Hughes W.T., Pizzo P.A., Wa-de J.C., et al. Evaluation of newanti-infective drugs for the treat-ment of febrile episodes in neu-tropenic patients. Clin Infect Dis1992; 15(Suppl 1):S206-15.
  • 36. Johnson M.P., Ramphal R.β-Lac-tam-resistantEnterobacterbactere-mia in febrile neutropenic patientsreceiving monotherapy. J Infect Dis1990; 162:981-3.
  • 37. Anaissie E.J., Fainstein V., Bo-dey G.P., et al. Randomized trial ofbeta-lactam regimens in febrileneutropenic cancer patients. Am JMed 1988; 84:581-9.
  • 38. Bodey G.P., Fainstein V., El-ting L.S., et al. Beta-lactam regi-mens for the febrile neutropenicpatient. Cancer 1990; 65:9-16.
  • 39. Malik I.A., Khan W.A., Karim M.,et al. Feasibility of outpatientmanagement of fever in cancerpatients with low-risk neutropenia:results of a prospective randomizedtrial. Am J Med 1995; 98:224-31.
  • 40. Mullen C.A., Petropoulos D.,Roberst W.M., et al. Outpatienttreatment of fever and neutropeniafor low risk pediatric cancerpatients. Cancer 1999; 86:126-34.
  • 41. Garcia-Carbonero R., Cortes-Funes H. Outpatient therapy withoral ofloxacin for patients with lowrisk neutropenia and fever: aprospective, randomized clinicaltrial. Cancer 1999; 85:213-9.
  • 42. Rolston K.V.I. New trends in pati-ent management: risk-based thera-py for febrile patients with neu-tropenia. Clin Infect Dis 1999;29:515-21.
  • 43. Freifeld A., Marchigiani D.,Walsh T., et al. A double-blind com-parison of empirical oral and intra-venous antibiotic therapy for low-risk febrile patients with neutrope-nia during cancer chemotherapy.N Engl J Med 1999; 341:305-11.
  • 44. Aquino V.M., Tkaczewski I., Bu-chanan G.R. Early discharge oflow-risk febrile neutropenic chil-dren and adolescents with cancer.Clin Infect Dis 1997; 25:74-8.
  • 45. Kern W.V., Cometta A., DeBock R.,et al. Oral versus intravenous empi-rical antimicrobial therapy for feverin patients with granulocytopeniawho are receiving cancer chemo-therapy. N Engl J Med 1999;341:312-8.
  • 46. Klaasseen R.J.,Goodman R.,Pham B.A., Doyle J.J. «Low-risk»prediction rule for pediatric oncolo-gy patients presenting with feverand neutropenia. J Clin Oncol2000; 18:1012-9.
  • 47. Rackoff W.R., Gonin R., Robin-son C., et al. Predicting the risk ofbacteremia in children with feverand neutropenia. J Clin Oncol1996; 14:919-24.
  • 48. Jones G.R., Konsler G.K., Duna-way R.P., et al. Risk factors forrecurrent fever after the disconti-nuation of empiric antibiotic thera-py for fever and neutropenia inpediatric patients with a malignan-cy or hematologic condition. JPediatr 1994; 124:703-8.
  • 49. Elting L.S., Rubenstein E.B., Rols-ton K.V.I., et al. Outcome of bac-teremia in patients with cancer andneutropenia: observations from twodecades of epidemiological andclinical trials. Clin Infect Dis 1997;25:247-59.
  • 50. Klastersky J., Paesmans M.,Rubenstein E.B., et al. The multina-tional association for supportivecare in cancer risk index: a multina-tional scoring system for identifylow-risk febrile neutropenic cancerpatients. J Clin Oncol 2000;18:3038-51.
  • 51. Talcott J.A., Siegel R.D., Fin-berg R., et al. Risk assessment incancer patients with fever and neu-tropenia: a prospective, two-centervalidation of a prediction rule. JClin Oncol 1992; 10:316-22.
  • 52. Shenep J.L., Flynn P.M., Ba-ker D.K., et al. Oral cefixime is si-milar to continued intravenousantibiotics in the empirical treat-ment of febrile neutropenic chil-dren with cancer. Clin Infect Dis2001; 32:36-43.
  • 53. Paganini H.R., Sarkis C.M., DeMar-tino M.G., et al. Oral admini-stration of cefixime to lower riskfebrile neutropenic children withcancer. Cancer 2000; 88:2848-52.
  • 54. Rubinstein E., Lode H., Grassi C.Ceftazidime monotherapy vs. cef-triaxone/tobramycin for serioushospital-acquired gram-negativeinfections. Antibiotic Study Group.Clin Infect Dis 1995; 20:1217-28.
  • 55. Winston D.J., Ho W.G., Bruck-ner D.A., Champlin R.E. Beta-lac-tam antibiotic therapy in febrilegranulocytopenic patients: a ran-domized trial comparing cefopera-zone plus piperacillin, ceftazidimeplus piperacillin, and imipenemalone. Ann Intern Med 1991;115:849-59.
  • 56. De Pauw B.E., Deresinski S.C.,Feld R., et al.Ceftazidime com-pared with piperacillin and tobra-mycin for the empiric treatment offever in neutropenic patients withcancer: a multicenter randomizedtrial. Ann Intern Med 1994;120:834-44.
  • 57. Pizzo P.A., Hathorn J.W., Hie-menz J., et al. A randomized trialcomparing ceftazidime alone withcombination antibiotic therapy incancer patients with fever and neu-tropenia. N Engl J Med 1986;315:552-8.
  • 58. Gardembas-Pain M., Desablens B.,Sensebe L., et al. Home treatmentof febrile neutropenia: an empiricaloral antibiotic regimen. Ann Oncol1991; 2:485-7.
  • 59. Malik I.A., Abbas A., Karim M.Randomized comparison of oralofloxacin alone with combination ofparenteral antibiotics in neu-tropenic febrile patients. Lancet1992; 339(8801):1092-6.
  • 60. Wang F.D., Liu C.Y., Hsu H.C., etal. A comparative study of cefepimeversus ceftazidime as empiric thera-py of febrile episodes in neu-tropenic patients. Chemotherapy1999; 45:370-9.
  • 61. Biron P., Fuhrmann C., Cure H., etal. Cefepime versus imipenem-cilas-tatin as empirical monotherapy in400 febrile patients with shortduration neutropenia: CEMIC. JAntimicrob Chemother 1998;42:511-8.
  • 62. Lindbald R., Rodjer S., Adrians-son M., et al. Empiric monotherapy for febrile neutropenia–a rando-mized study comparing meropenemwith ceftazidime. Scand J Infect Dis1998; 30:237-43.
  • 63. Behre G., Link H., Maschmeyer G.,et al. Meropenem monotherapyversus combination therapy withceftazidime and amikacin for empi-rical treatment of febrile neu-tropenic patients. Ann Hematol1998; 76:73-80.
  • 64. Bohme A., Shah P.M., Stille W., etal. Piperacillin/tazobactam versuscefepime as initial empirical antimi-crobial therapy in febrile neutrope-nia patients: a prospective rando-mized pilot study. Eur J Med Res1998; 3:324-30.
  • 65. Del Favero A., Menichetti F., Mar-tino P., et al. A multicenter, double-blind, placebo-controlled trial com-paring piperacillin-tazobactamwith and without amikacin asempiric therapy for febrile neu-tropenia. Clin Infect Dis 2001;33:1295-301.
  • 66. Engervall P., Kalin M., Dorn-busch K., et al. Cefepime as empiri-cal monotherapy in febrile patientswith hematological malignanciesand neutropenia: a randomized, sin-gle-center phase II trail. J Chemo-ther 1999; 11:278-86.
  • 67. Ozyilkan O., Yalcintas U., Bas-kan S. Imipenem-cilastatin versussulbactam-cefoperazoneplusamikacin in the initial treatment offebrile neutropenic cancer patients.Korean J Intern Med 1999;14:15-9.
  • 68. Ramphal R. Is monotherapy forfebrile neutropenia still a viablealternative? Clin Infect Dis 1999;29:508-14.
  • 69. Akova M., Akan H., Korten H., etal. Comparison of meropenem withamikacin plus ceftazidime in theempirical treatment of febrile neu-tropenia: a prospective randomizedmulticentre trial in patients with-out previous prophylactic antibio-tics. Meropenem Study Group ofTurkey. Int J Antimicrob Agents1999; 13:15-9.
  • 70. Yamamura D., Gacalp R., Car-lisle P., et al. Open randomized stu-dy of cefepime versus piperacillin –gentamicin for treatment of febrileneutropenic cancer patients.Antimicrob Agents Chemother1997; 41:1704-8.
  • 71. Cometta A., Calandra T., Gaya H.,et al. Monotherapy with merope-nem versus combination therapywith ceftazidime plus amikacin asempiric therapy for fever in granu-locytopenic patients with cancer.Antimicrob Agents Chemother1996; 40:1108-15.
  • 72. RaadI.I., Abi-Said D., Rol-ston K.V., et al. How should imipe-nem – cilastatin be used in thetreatment of fever and infection inneutropenic cancer patients?Cancer 1998; 82:2449-58.
  • 73. Oblon D., Ramphal R. A randomizedtrial of cefepime vs. ceftazidime asinitial therapy for patients with pro-longed fever and neutropenia afterintensive chemotherapy [abstract].Proceedings of the annual meetingof the American Association forCancer 1993; 34:1362A.
  • 74. Feld R., DePauw B., Berman S., etal. Meropenem versus ceftazidimein the treatment of cancer patientswith febrile neutropenia: arandomized, double-blind trial. JClin Oncol 2000; 18:3690-8.
  • 75. Owens R.C., Owens C.A., HollowayW.J. Reduction in vancomycin con-sumption in patients with fever andneutropenia [abstract 458]. ClinInfect Dis 2000; 31:291.
  • 76. Vandercam B., Gerain J., Hum-blet Y., et al. Meropenem versusceftazidime as empirical monothe-rapy for febrile neutropenicpatients. Ann Hematol 2000;79:152-7.
  • 77. Johnson P.R.E., Liu Yin J.A., To-oth J.A. High dose intravenousciprofloxacin in febrile neutropenicpatients. J Antimicrob Chemother1990; 26:101-7.
  • 78. Johnson P.R., Liu Yin J.A., To-oth J.A. A randomized trial of high-dose ciprofloxacin versus azlocillinand netilmicin in the empiricaltherapy of febrile neutropenicpatients. J Antimicrob Chemother1992; 30:203-14.
  • 79. Winston D.J., Lazarus H.M., Beve-ridge R.A., et al. Randomized, dou-ble-blind multicenter trail compa-ring clinafloxacin with imipenem asempirical monotherapy for febrilegranulocytopenic patients. ClinInfect Dis 2001; 32:381-90.
  • 80. Malik I.A., Abbas Z., Karim M.Randomized comparison of oralofloxacin alone with combination ofparenteral antibiotics in neu-tropenic febrile patients. Lancet1992; 339:1092-6.
  • 81. Meunier F., Zinner S.H., Gaya H.,et al. Prospective randomized eva-luation of ciprofloxacin versuspiperacillin plus amikacin forempiric antibiotic therapy of febrilegranulocytopenic cancer patientswith lymphomas and solid tumor.European Organization forResearch on Treatment of CancerInternational Antimicrobial The-rapy Cooperative Group. Anti-microb Agents Chemother 1991;35:873-8.
  • 82. Klastersky J., Vamecq G., Cap-pel R., Swings G., Vandenborre L.Effects of the combination of gen-tamicin and carbenicillin on thebactericidal activity of serum. JInfect Dis 1972; 125:183-6.
  • 83. Sepkowitz K.A., Brown A.E., Arm-strong D. Empirical therapy forfebrile, neutropenic patients: persis-tence of susceptibility of gram-ne-gative bacilli to aminoglycosideantibiotics. Clin Infect Dis 1994;19:810-1.
  • 84. Brown A.E., Kiehn T.E., ArmstrongD. Bacterial resistance in thepatient with neoplastic disease.Infect Dis Clin Pract 1995; 4:136-44.
  • 85. International Antimicrobial Thera-py Cooperative Group of theEuropean Organization for Rese-arch and Treatment of Cancer.Efficacy and toxicity of single dailydoses of amikacin and ceftriaxoneversus multiple daily doses ofamikacin and ceftazidime for infec-tion in patients with cancer andgranulocytopenia. Ann Intern Med1993; 119:584-93.
  • 86. Diekema D.J., Jones R.N.,Rolston K.V.I. Antimicrobial acti-vity of gatifloxacin compared toseven other compounds testedagainst gram-positive organismsisolated at 10 cancer-treatmentcenters. Diagn Microbiol Infect Dis1999; 34:37-43.
  • 87. Rolston K.V.I.,LaBlanc B.M.,Balakrishnan M., et al.In vitro activity of moxifloxacin againstgram-negative isolates from cancerpatients [abstract 2324]. In:Program and abstracts of the 40thInterscience Conference on Anti-microbial Agents and Chemo-therapy (Toronto). Washington,DC: American Society forMicrobiology, 2000.
  • 88. Rolston K.V.I,LeBlanc H.,Ho D.H.In vitroactivity of gati-floxacin against gram-negative iso-lates from cancer patients [abstract359]. Proceedings of the 39thInterscience Conference onAntimicrobial Agents and Chemo-therapy(SanFrancisco).Washington, DC: AmericanSociety for Microbiology, 1999.
  • 89. Papadimitris C., Dimopoulos M.A.,Kostis E., et al. Outpatient treat-ment of neutropenic fever with oralantibiotics and granulocyte colony-stimulating factor. Oncology 1999;57:127-30.
  • 90. Peacock J.E., Wade J.C., Laza-rus H.M., et al. Ciprofloxa-cin/piperacillin vs. tobramycin/pi-peracillin as empiric therapy forfever in neutropenic cancer pati-ents, a randomized, double-blindtrial [abstract 373]. Proceedings ofthe 37th Interscience Conferenceon Antimicrob Agents and Chemo-therapy (Toronto). Washington,DC: American Society for Micro-biology, 1997.
  • 91. Chatzinikalaou I., Abi-Said D.,Bodey G.P., et al. Recent experi-ence withPseudomonas aeruginosabacteremia in patients with cancer:retrospective analysis of 245episodes. Arch Intern Med 2000;160:501-9.
  • 92. Centers for Disease Control andPrevention. Recommendations forpreventing the spread of van-comycin resistance: recommenda-tions of the Hospital InfectionControl Practices AdvisoryCommittee (HIC-PAC). MMWRMorb Mortal Wkly Rep 1995;44(RR-12):1-13.
  • 93. Feld R. Vancomycin as part of ini-tial empirical antibiotic therapy forfebrile neutropenia in patients withcancer: pros and cons. Clin InfectDis 1999; 29:503-7.
  • 94. Shenep J.L., Hughes W.T.,Roberson P.K., et al. Vancomycin,ticarcillin, and amikacin comparedwith ticarcillin-clavulanate andamikacin in the empirical treatmentof febrile, neutropenic childrenwith cancer. N Engl J Med 1988;319:1053-8.
  • 95. Elting L.S., Bodey G.P., Keefe B.H.Septicemia and shock syndrome dueto viridans streptococci: a case-con-trol study of predisposing factors.Clin Infect Dis 1992; 14:1201-7.
  • 96. Traub W.H., Spohr M., Bauer D.In vitroadditive effect of imipenemcombined with vancomycin againstmultiple-drug resistant, coagulase-negative staphylococci. ZentralblMikrobiol Hyg [A] 1986; 262:361-9.
  • 97. Harvey W.H., Harvey J.H., Mosko-witz M.J. Ciprofloxacin/vanco-mycin (C/V) as initial empirictherapy in febrile neutropenicleukemia/lymphoma patients (pts)with indwelling venous accessdevices: preliminary results of aneffective regimen with reduced hos-pital stay [abstract A1639]. In:Proceedings of the annual meetingof the American Society of ClinicalOncology, 1994. 13.
  • 98. Kelsey S.M., Shaw E., Newland A.C.Aztreonam plus vancomycin versusgentamicin plus piperacillin asempirical therapy for the treatmentof fever in neutropenic patients: arandomized controlled study. JChemother 1992; 4:107-13.
  • 99. Raad I.I., Whimbey E.E., Rols-ton K.V.I., et al. A comparison ofaztreonam plus vancomycin andimipenem plus vancomycin as ini-tial therapy for febrile neutropeniccancer patients. Cancer 1996;77:1386-94.
  • 100. Ramphal R., Bolger M., Oblon D.J.,et al. Vancomycin is not an essentialcomponent of the initial empirictreatment regimen for febrile neu-tropenic patients receiving cef-tazidime: a randomized prospectivestudy. Antimicrob Agents Chemo-ther 1992; 36:1062-7.
  • 101. Cony-Makhoul P., Brossard G.,Marit G., et al. A prospective studycomparing vancomycin andteicoplanin as second-line empirictherapy for infection in neutropenicpatients. Br J Haematol 1990; 76(Suppl 2):35-40.
  • 102. Pico J.L., Marie J.P., Chiche D., etal. Should vancomycin be usedempirically in febrile patients withprolonged and profound neutrope-nia? Results of a randomized trial.Eur J Med 1993; 2:275-80.
  • 103. Viscoli C., Moroni C., Boni L., etal. Ceftazidime plus amikacin ver-sus ceftazidime plus vancomycin asempiric therapy in febrile neu-tropenic children with cancer. RevInfect Dis 1991; 13:397-404.
  • 104. Rikonen P. Imipenem comparedwith ceftazidime plus vancomycin asinitial therapy for fever in neu-tropenic children with cancer.Pediatr Infect Dis J 1991; 10:918-23.
  • 105. Chow A.W., Jewesson P.J., Kurei-shi A., et al. Teicoplanin versus van-comycin in the empirical treatmentof febrile neutropenic patients. EurJ Haematol Suppl 1993; 54:18-24.
  • 106. Kureishi A., Jewesson P.J., Rubin-ger M., et al. Double-blind compari-son of teicoplanin versus van-comycin in febrile neutropenicpatients receiving concomitanttobramycin and piperacillin: effecton cyclosporin-associated nephro-toxicity. Antimicrob AgentsChemother 1991; 35:2246-52.
  • 107. Rubinstein E., Cammarata S.K.,Oliphant T.H., et al. Linezolid(PNU-100766) versus vancomycinin the treatment of hospitalizedpatients with nosocomial pneumo-nia: a randomized, double-blind,multicenter study. Clin Infect Dis2001; 32:402-12.
  • 108. Freifeld A., Pizzo P. Use of fluoro-quinolones for empirical manage-ment of febrile neutropenia in pedi-atric cancer patients. Pediatr InfectDis J 1997; 16:140-6.
  • 109. Charnas R., Luthi A.R., Ruch W.Once daily ceftriaxone plus amika-cin vs. three times daily ceftazidimeplus amikacin for treatment offebrile neutropenic children withcancer. Pediatr Infect Dis J 1997;16:346-53.
  • 110. Eggimann P., Glauser M.P., AounM., Meunier F., Calandra T. Cefe-pime monotherapy for the empiricaltreatment of fever in granulocy-topenic cancer patients. J Anti-microb Chemother 1993; 32(SupplB):151-63.
  • 111. Bow E.J., Loewen R., Vaughan D. Reduced requirement for antibiotictherapy targeting gram-negativeorganisms in febrile, neutropenicpatients with cancer who arereceiving antibacterial chemopro-phylaxis with oral quinolones. ClinInfect Dis 1995; 20:907-12.
  • 112. Elting L.S., Rubenstein E.B.,Rolston K., et al. Time to clinicalresponse: an outcome of antibiotictherapy of febrile neutropenia withimplications for quality and cost ofcare. J Clin Oncol 2000; 18:3699-706.
  • 113. Mullen C.A., Buchanan G.R. Earlyhospital discharge of children withcancer treated for fever and neu-tropenia: identification and ma-nagement of the low-risk patient. JClin Oncol 1990; 8:1998-2004.
  • 114. Jones G.R., Konsler G.K., Duna-way R.P., et al. Risk factors forrecurrent fever after the disconti-nuation of empiric antibiotic thera-py for fever and neutropenia inpediatric patients with a malignan-cy or hematologic condition. JPediatr 1994; 124:703-8.
  • 115. Griffin T.C., Buchanan G.R. He-matologic predictors of bone mar-row recovery in neutropenicpatients hospitalized for fever:implications for discontinuation ofantibiotics and early discharge fromthe hospital. J Pediatr 1992;121:28-33.
  • 116. Santolaya M.E., Villarroel M.,Avendano L.F., et al. Disconti-nuation of antimicrobial therapyfor febrile, neutropenic childrenwith cancer: a prospective study.Clin Infect Dis 1997; 25:92-7.
  • 117. Woo P.C., Wong S.S., Lum P.N.,et al. Cell-wall deficient bacteriaand culture-negative febrileepisodes in bone marrow recipients.Lancet 2001; 357:675-9.
  • 118. Pizzo P.A., Robichaud K.J.,Gill F.A., Witebsky F.G. Empiricantibiotic and antifungal therapyfor cancer patients with prolongedfever and granulocytopenia. Am JMed 1982; 72:101-11.
  • 119. EORTC International Antimicro-bial Therapy Cooperative ProjectGroup. Empiric antifungal therapyin febrile granulocytopenic pati-ents. Am J Med 1989; 86:668-72.
  • 120. Walsh T.J., Finberg R.W.,Arndt C., et al. Liposomal ampho-tericin B for empirical therapy inpatients with persistent fever andneutropenia. National Institute ofAllergy and Infectious DiseasesMycoses Study Group. N Engl JMed 1999; 340:764-71.
  • 121. Wingard J.R., White M.H., Anais-sie E., et al. A randomized, double-blind comparative trial evaluatingthe safety of liposomal ampho-tericin B versus amphotericin lipidcomplex in the empirical treatmentof febrile neutropenia. Clin InfectDis 2000; 31:1155-63.
  • 122. Fleming R.V., Kantarjian H.M.,Husni R., et al. Comparison ofamphotericin B lipid complex(ABLC) vs. AmBisome in the treat-ment of suspected or documentedfungal infections in patients withleukemia. Leuk Lymphoma 2001;40:511-20.
  • 123. Viscoli C., Castagnola E., vanLint M.T., et al. Fluconazole versusamphotericin B as empirical antifun-gal therapy of unexplained fever ingranulocytopenic cancer patients.Eur J Cancer 1996; 32A:814-20.
  • 124. Winston D.J., Hathorn J.W.,Schuster M.G., et al. A multi-centerrandomized trial of fluconazole ver-sus amphotericin B for empiricantifungal therapy of febrile neu-tropenic patients with cancer. Am JMed 2000; 108:282-9.
  • 125. Bow E.J., Laverdiere M., Rot-stein C. A systematic review of theefficacy of azoles and lipid-basedformulations of amphotericin B asempirical antifungal therapy in per-sistently febrile neutropenicpatients despite broad-spectrumantibacterial therapy [abstract]. In:Program and abstracts of the 40thInterscience Conference on Anti-microbial Agents and Chemo-therapy (Toronto). Washington,DC: American Society for Micro-biology, 2000.
  • 126. Boogaerts M., Winston D.J.,Bow E.J., et al. Intravenous andoral itraconazole versus intra-venous amphotericin B deoxycho-late as empirical antifungal therapyfor persistent fever in neutropenicpatients with cancer who arereceiving broad-spectrum antibac-terial therapy: a randomized, con-trolled trial. Ann Intern Med 2001;135:412-22.
  • 127. Pizzo P.A., Robichaud K.J.,Gill F.A., et al. Duration of empiricantibiotic therapy in granulocy-topenic patients with cancer. Am JMed 1979; 67:194-200.
  • 128. Hughes W.T., Patterson G. Post-sepsis prophylaxis in cancer pati-ents. Cancer 1984; 53:137-41.
  • 129. Crane L., Komskian S., Sauber A.,et al. Antibiotic therapy in febrileneutropenic patients: what is theoptimum duration of therapy?[Abstract]. Proceedings of the 28thInterscience Conference on Anti-microbial Agents and Chemothe-rapy (Los Angeles). Washington,DC: American Society for Micro-biology, 1988:114.
  • 130. DeMarie S., Van den Broek P.J.,Willemze R., et al. Strategy forantibiotic therapy in febrile neu-tropenic patients on selectiveantibiotic decontamination. Eur JClin Microbiol Infect Dis 1993;12:897-906.
  • 131. Bash R.O., Katz J.A., Cash J.V., etal. Safety and cost effectiveness ofearly hospital discharge of lowerrisk children with cancer admittedfor fever and neutropenia. Cancer1994; 74:189-96.
  • 132. Joshi J.H., Schimpff S.C., Ten-ney J.H., et al. Can antibacterialtherapy be discontinued in persis-tently febrile granulocytopeniccancer patients? Am J Med 1984;76:450-7.
  • 133. Cornelissen J.J., Rozenberg-Ars-ka M., Dekker A.W. Disconti-nuation of intravenous antibiotictherapy during persistent neu-tropenia in patients receiving pro-phylaxis with oral ciprofloxacin.Clin Infect Dis 1995; 21:1300-2.
  • 134. Santhosh-Kumar C.R., Aja-rim D.S.S., Harakati M.S., et al.Ceftazidime and amikacin as empi-ric treatment of febrile episodes inneutropenic patients in SaudiArabia. J Infect 1992; 25:11-9.
  • 135. Heussel C.P., Hauczor H.U.,Heussel G., et al. Early detection ofpneumonia in febrile Neutropenicpatients: use of thin-section CT.AJR Am J Roentgenol 1997;169:1347-53.
  • 136. Bartley D.L., Hughes W.T., Parvey L.S., et al. Computed tomogra-phy of hepatic and splenic fungalabscesses in leukemic children.Pediatr Infect Dis 1982; 1:317-21.
  • 137. Flynn P.M., Shenep J.L., Craw-ford R., et al. Use of abdominalcomputed tomography for identify-ing disseminated fungal infection inpediatric cancer patients. ClinInfect Dis 1995; 20:964-70.
  • 138. Talbot G.H., Provencher M.,Cassileth P.A. Persistent fever afterrecovery from granulocytopenia inacute leukemia. Arch Intern Med1988; 148:129-35.
  • 139. Baglin T.P., Gray J.J., Mar-cus R.E., Wreghitt T.G. Antibioticresistant fever associated withherpes simplex virusinfection in neu-tropenic patients with haematolo-gical malignancy. J Clin Pathol1989; 42:1255-8.
  • 140. Bhatia S., McCullough J., Per-ry E.H. Granulocyte transfusions:efficacy in treating fungal infec-tions in neutropenic patients fol-lowing bone marrow transplanta-tion. Transfusion 1994; 34:226-32.
  • 141. Catalano L., Fiontana R., Scar-pato N., et al. Combined treatmentwith amphotericin B and granulo-cyte transfusion from G-CSF-sti-mulated donors in an aplasticpatient with invasive aspergillosisundergoing bone marrow trans-plantation. Haematologica 1997;82:71-2.
  • 142. Dignani C.M., Anaissie E.J.,Hester J.P., et al. Treatment of neu-tropenia-related fungal infectionswith granulocyte colony-stimula-ting factor – elicited white bloodcell transfusions: a pilot study.Leukemia 1997; 11:1621-30.
  • 143. Hubel K., Dale D.C., Engert A.,Liles W.C. Current status of granu-locyte (neutrophil) transfusiontherapy for infectious diseases. JInfect Dis 2001; 183:321-8.
  • 144. Riikonen P.,Saarinen U.M.,Makipernaa A. Recombinant hu-man granulocyte-macrophage colo-ny-stimulating factor in the treat-ment of febrile neutropenia: a dou-ble blind placebo-controlled studyin children. Pediatr Infect Dis J1994; 13:197-202.
  • 145. Anaissie E.J., Vartivarian S.,Bodey G.P., et al. Randomizedcomparison between antibioticsalone and antibiotics plus granulo-cyte-macrophage colony-stimula-ting factor (Escherichia coli-derived) in cancer patients withfever and neutropenia. Am J Med1996; 100:17-23.
  • 146. Biesma B., deVries E.G., Wil-lemse P.H. Efficacy and tolerabilityof recombinant human granulo-cyte-macrophage colony-stimula-ting factor in patients withchemotherapy-related leukopeniaand fever. Eur J Cancer 1990;26:932-6.
  • 147. Ravaud A., Chevreau C., Cany L.,et al. Granulocyte-macrophagecolony-stimulating factor inpatients with neutropenic chemo-therapy regimens: results of a ran-domized phase III trial. J ClinOncol 1998; 16:2930-6.
  • 148. Maher D.W., Lieschke G.J., Gre-en M., et al. Filgrastim in patientswith chemotherapy-induced febrileneutropenia–a double-blind, place-bo-controlled trial. Ann InternMed 1994; 121:492-501.
  • 149. Vellenga E., Uyl-de Groot C.A., deWit R., et al. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulatingfactor in patients with chemothera-py related febrile neutropenia. JClin Oncol 1996; 14:619-27.
  • 150. Liang D.C., Chen S.H., Lean S.F.Role of granulocyte colony-stimu-lating factor as adjunct therapy forsepticemia in children with acuteleukemia. Am J Hematol 1995;48:76-81.
  • 151. Mitchell P.L.R., Morland B.J.,Dick G., et al. Clinical benefits andcost savings of interventionalG-CSF therapy in patients withfebrile neutropenia followingchemotherapy [abstract]. Blood1995; 86 (Suppl 1): 500A.
  • 152. Mayordomo J.I., Rivera F., Diaz-Puente M.T., et al. Improving treat-ment of chemotherapy-inducedneutropenic fever by administra-tion of colony-stimulating factors. JNatl Cancer Inst 1995; 87:803-8.
  • 153. Mitchell P.L., Morland B., Ste-vens M.C., et al. Granulocytecolony-stimulating factor in estab-lished febrile neutropenia: a ran-domized study of pediatric patients.J Clin Oncol 1997; 15:1163-70.
  • 154. Michon J.M., Hartmann O., Bou-fett E., et al. An open-label, multi-centre, randomised phase 2 study ofrecombinant human granulocytecolony-stimulating factor (filgras-tim) as an adjunct to combinationchemotherapy in paediatric patientswith metastatic neuroblastoma. EurJ Cancer 1998; 34:1063-9.
  • 155. Yoshida M., Karasawa M., Na-ruse T., et al. Effect of granulocyte-colony stimulating factor on empirictherapy with flomoxef sodium andtobramycin in febrile neutropenicpatients with hematological malig-nancies. Kanetsu HematologicalDisease and Infection Study Group.Int J Hematol 1999; 69:81-8.
  • 156. Ozer H., Armitage J.O., Ben-nett C.L., et al. 2000 update of re-commendations for the use ofhematopoietic colony-stimulatingfactors: evidence-based clinicalpractice guidelines. J Clin Oncol2000; 18:3558-85.
  • 157. Hidalgo M., Hornedo J., Lumb-reras C., et al. Lack of ability ofciprofloxacin-rifampin prophylaxisto decrease infection-related mor-bidity in neutropenic patients givencytotoxic therapy and peripheralblood stem cell transplants. Anti-microb Agents Chemother 1997;41:1175-7.
  • 158. Engels E.A., Lau J., Barza M.Efficacy of quinolone prophylaxisin neutropenic cancer patients: ameta-analysis. J Clin Oncol 1998;16:1179-87.
  • 159. Munzo L., Martino R., Subira M.,et al. Intensified prophylaxis offebrile neutropenia with ofloxacinplus rifampin during severe short-duration neutropenia in patientwith lymphoma. Leuk Lymphoma1999; 34:585-9.
  • 160. Hughes W.T.,Rivera G.K.,Schell M.J., et al. Successful inter-mittent chemoprophylaxis forPneumocystis cariniipneumonitis.N Engl J Med 1987; 316:1627-32.
  • 161. Murphy M., Brown A.E., Sepko-witz A., et al. Fluoroquinolone pro-phylaxis for the prevention of bac-terial infections in patients withcancer – is it justified? Clin InfectDis 1997; 25:346-7.
  • 162. Kern W., Kurrle E. Ofloxacin versus trimethoprim-sulfamethoxazolefor prevention of infection in pati-ents with acute leukemia andgranulocytopenia. Infection 1991;19:73-80.
  • 163. Bow E.J., Mandell L.A., Louie T.J.,et al. Quinolone-based chemopro-phylaxis in neutropenic patients:effect of augmented gram-positiveactivity on infectious morbidity.Ann Intern Med 1996; 125:183-90.
  • 164. Harvathova Z., Spanik S., Sufliar-sky J., et al. Bacteremia due tomethicillin-resistant staphylococcioccurs more frequently in neu-tropenia patients who receivedantimicrobial prophylaxis and isassociated with higher mortality incomparison of methicillin-sensitivebacteremia. Int J AntimicrobAgents 1998; 10:55-8.
  • 165. International Antimicrobial The-rapy Cooperative Group of theEuropean Organization for Rese-arch and Treatment and Cancer.Reduction of fever and streptococ-cal bacteremia in granulocytopenicpatients with cancer: a trial of oralpenicillin V or placebo combinedwith pefloxacin. JAMA 1994;272:1183-9.
  • 166. Goodman J.L.,Winston D.J.,Greenfield A., et al. A controlledtrial of fluconazole to prevent fun-gal infections in patients undergo-ing bone marrow transplantation. NEngl J Med 1992; 326:845-51.
  • 167. Ellis M.E., Clink H., Ernst P., et al.Controlled study of fluconazole inthe prevention of fungal infectionsin neutropenic patients withhaematological malignancies andbone marrow transplant recipients.Eur J Clin Microbiol Infect Dis1994; 13:3-11.
  • 168. Marr K.A., Seidel K., White T.C.,et al. Candidemia in allogenic bloodand marrow transplant recipients:evolution of risk factors after theadoption of prophylactic flucona-zole. J Infect Dis 2000; 181:309-16.
  • 169. Wingard J.R., Merz W.G., Rinal-di M.G., et al. Increase inCandidakruseiinfection among patientswith bone marrow transplantationand neutropenia treated prophylac-tically with fluconazole. N Engl JMed 1991; 325:1274-7.
  • 170. Rotstein C., Bow E.G., Laver-diere M., et al. Randomized place-bo-controlled trial of fluconazoleprophylaxis for neutropenicpatients: benefit based on purposeand intensity of cytotoxic therapy.Clin Infect Dis 1999; 28:331-40.
  • 171. Centers for Disease Control andPrevention. Guidelines for preven-ting opportunistic infections amonghematopoetic stem cell transplantrecipients—recommendations ofCDC, the Infectious Diseases Soci-ety of America, and the AmericanSociety of Blood and Transplan-tation. MMWR Morb MortalWkly Rep 2000; 49(RR-10):1-125.
  • 172. Menichetti F., Flavero A.D.,Martion P., et al. Itraconazole oralsolution as prophylaxis for fungalinfections in neutropenic patientswith hematologic malignancies: arandomized, placebo-controlled,double-blind, multicenter trial.Clin Infect Dis 1999; 28:250-5.
  • 173. Nucci M., Biasoli I., Akiti T., et al.A double-blind, randomized, place-bo-controlled trial of itraconazolecapsules as antifungal prophylaxisfor neutropenic patients. ClinInfect Dis 2000; 30:300-5.
  • 174. Bow E.J., Laverdiere M., Lus-sier N., Rotstein C. Antifungal pro-phylaxis in neutropenic patients: ameta-analysis of randomized-con-trolled trials [abstract 339A].Blood 1999; 94(Suppl 1):339A.
  • 175. Rolston K.V.I. Outpatient mana-gement of febrile, neutropenicpatients. Infections in Medicine1995; 12:12-5.
  • 176. Talcott J.A., Whalen A., Clark J.Home antibiotic therapy for low-risk cancer patients with fever andneutropenia: a pilot study of 30patients based on a validated pre-diction rule. J Clin Oncol 1994;12:107-14.
  • 177. DiNubile M.J. Stopping antibiotictherapy in neutropenic patients.Ann Intern Med 1988; 108:289-92.
  • 178. Lau R.C., Doyle J.J., Freed-man M.H., et al. Early discharge ofpediatric febrile neutropenic cancerpatients by substitution of oral forintravenous antibiotics. J PediatrHematol Oncol 1994; 11:417-21.
  • 179. Mullen C.A., Petropoulos D., Ro-berts W.M., et al. Economic andresource utilization analysis of out-patient management of fever andneutropenia in low-risk pediatricpatients with cancer. J PediatrHematol Oncol 1999; 21:212-8.
  • 180. DeLalla F. Antibiotic treatment offebrile episodes in neutropenic can-cer patients: clinical and economicconsiderations. Drugs 1997;53:789-804.
  • 181. Klastersky J. Current attitudes fortherapy for febrile neutropenia withconsideration to cost-effectiveness.Curr Opin Oncol 1998; 10:284-90.
  • 182. Gibson J., Johnson L., Snowdon L.,et al. A randomized dosage study ofceftazidime with single dailytobramycin for the empirical mana-gement of febrile neutropenia inpatients with hematological dise-ases. Int J Hematol 1994; 60:119-27.
  • 183. Lyman G.H., Kuderer N.M., Bla-ducci L. Economic impact of granu-lopoiesis stimulating agents on themanagement of febrile neutropenia.Curr Opin Oncol 1998; 10:291-6.
Просмотров
0 Аннотация
0 PDF
0 Цитирования
Поделились